[caption id=“attachment_81355” align=“aligncenter” width=“860”]  In a mega $4 billion deal, Sun Pharma is buying troubled Indian peer Ranbaxy in an all-stock deal. However, Sun is paying is paying less than what Japan’s Daiichi had paid when it acquired Ranbaxy in 2008 from its erstwhire promoters Malvinder and Shivinder Singh for $4.6 billion. Source: Sun Pharma’s investor presentation[/caption]
            End of Article


)
)
)
)
)
)
)
)
)
